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The use of an in vitro 3D melanoma model to predict in vivo
plasmid transfection using electroporation
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Abstract
A large-scale in vitro 3D tumor model was generated to evaluate gene delivery procedures in vivo.
This 3D tumor model consists of a “tissue-like” spheroid that provides a micro-environment
supportive of melanoma proliferation, allowing cells to behave similarly to cells in vivo. This
functional spheroid measures approximately 1 cm in diameter and can be used to effectively
evaluate plasmid transfection when testing various electroporation (EP) electrode applicators. In
this study, we identified EP conditions that efficiently transfect green fluorescent protein (GFP)
and interleukin 15 (IL-15) plasmids into tumor cells residing in the 3D construct. We found that
plasmids delivered using a 6-plate electrode applying 6 pulses with nominal electric field strength
of 500 V/cm and pulse-length of 20 ms produced significant increase of GFP (7.3-fold) and IL-15
(3.0–fold) expression compared to controls. This in vitro 3D model demonstrates the predictability
of cellular response toward delivery techniques, limits the numbers of animals employed for
transfection studies, and may facilitate future developments of clinical trials for cancer therapies in
vivo.
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1. Introduction
Many forms of in vitro three dimensional (3D) tumor models have been generated to address
how co-cultured cells behave compared to cells residing together in vivo [1–3].
Investigations have examined whether immortalized cell lines coaxed into a 3D environment
are able to preserve natural functions when grown as homo- or heterogeneous populations
[4,5]. In addition, the models may be used to determine appropriate parameters to translate
non-viral gene delivery methods in vivo. Wasungu et al., analyzed the permeability of cells
subjected to electroporation (EP) when organized on a synthetic matrix forming a micro-
scale 3D construct [6]. This group demonstrated an increase in the permeabilization of
layered cells when exposed to electric fields, suggesting a good model for testing gene
delivery techniques in vivo [7]. These studies raise two questions: (1) do complimenting cell
types such as keratinocytes and melanoma cells co-inhabiting an in vitro 3D construct cross
talk and promote functional activities similar to in vivo micro-environments and (2) can a
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large-scale 3D tumor model predict the transfection efficacy of particular plasmids delivered
with various EP conditions prior to testing them in pre-clinical animal models? To address
these questions, we analyzed how keratinocytes and melanoma cells mutually interact within
a functional 3D construct and how this model translates potential anti-tumor gene delivery
techniques in vivo.
Normally, keratinocytes (epidermal cells) and melanocytes (melanin producing cells) are
known to cross talk with one another in nature through cell–cell contact, adhesive properties
and growth factors. Ultraviolet exposure stimulates melanin production in melanocytes to
protect keratinocytes against DNA damage [8]. Melanocytes themselves can undergo many
aberrant genetic alterations either spontaneously or due to UV rays, which in turn may up-
regulate oncogenic properties and enhance tumor expansion [9]. Keratinocytes are known to
act in a tumor suppressive manner by enhancing integrins and adherent proteins such as E-
cadherin during early stages of aggressive human melanoma development. Keratinocytes
function to prevent tumor cells from migrating into deeper layers of the epidermis, while
melanoma cells can escape these suppressive signals by down-regulating E-cadherin and up-
regulating melanoma adhesion receptors [10,11]. The melanoma cell’s tumorigenic evasion
signals help dissociate keratinocyte integrins and adherent proteins, breaking the cross talk
capabilities [8,12,13]. Previously published studies have demonstrated that these cells types
require one another’s functional properties to maintain a homeostatic environment, which
suggests compatible co-existence with in a 3D model.
The 3D model described here was previously generated in a bioreactor [14]. Human
keratinocyte (HaCaT) aggregates were formed in a high aspect ratio vessel (HARV)
producing a “tissue-like” scaffolding which supported viable proliferation and
differentiation of melanoma (B16.F10) cells [14]. HaCaT cells were utilized to mimic
naturally occurring keratinocytes, a major component of the basal layer within the epidermis
which houses melanocytes [8,15]. In this previous study, HaCaT and B16.F10 cells were
able to coexist in the 3D model and actively undergo different mitotic phases of the cell
cycle; this was demonstrated by varying degrees of nuclear staining using a Ki67
proliferation marker. In addition, both cell types demonstrated the production of their own
extracellular matrix (ECM), detected by fibronectin staining. ECM provides structural
support of cells and makes up the basement membrane where epithelial cells reside [14,16–
18]. Additional studies indicate that cells grown in a 3D micro-environment may imitate
natural cellular functions more closely then cells grown as a monolayer in culture [19–21].
The purpose for generating this in vitro 3D tumor model was to identify EP parameters that
effectively deliver plasmid DNA into cultured cells. One important feature of the 3D tumor
model is the size of the spheroid, which measures approximately 1 cm in diameter [14]. This
is ideal for adapting in vitro EP parameters to predict effective EP conditions for in vivo
plasmid delivery. EP enhances transfection of naked DNA into a large number of cell and
tissue types [22]. Transfection of particular cells requires the optimization of the applied
voltage (nominal electric field strength), pulse width, pulse frequency and the use of the
appropriate EP electrode applicator. Important concepts to consider with respect to
delivering genes of interest into the 3D model with the electrode applicators include tissue
type, location (surface or internal location) and size of the area to be treated. The ability to
evaluate effective delivery using an in vitro large-scale 3D model prior to testing conditions
in vivo is currently unavailable and would be beneficial for optimizing various EP
conditions on different cell and tissue types. The identification of efficient non-viral gene
delivery methods in vitro would reduce utilization of preclinical animal models prior to
translating EP procedures in vivo.
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2. Materials and methods
2.1. Materials
Human HaCaT keratinocytes were provided as a generous gift from Dr. Mark Jaroszeski
University of South Florida College of Engineering. Mouse melanoma B16.F10 and human
melanoma SKMEL-5 were purchased from the American Type Culture Collection
(Manassas, VA). Human interleukin 15 plasmid (phIL-15) was a generous gift provided by
Dr. David B. Weiner University of Pennsylvania College of Medicine. Green Fluorescent
Protein plasmid pEGFP-N1 (GFP) was purchased from Clontech (Palo Alto, CA). All
plasmids were commercially prepared by Aldevron (Fargo, ND).
2.2. 3D spheroid construct
As previously described [10], 3–5 × 106 cells of HaCaT were seeded into four T275 flasks
grown in DMEM (Media Tech Manassas, VA) containing 0.2% gentamycin (MidSci, St.
Louis, MO), and 10% Fetal Bovine Serum (FBS) (Atlanta Biologicals, Lawrenceville, GA).
After 2–3 days, confluent cells were trypsinized with 1× trypsin without EDTA (Atlanta
Biologicals, Lawrenceville, GA) and viability was determined using trypan blue staining.
On Day 0, 35–50 × 106 live HaCaT cells were seeded into 10 mL HARVs (Synthecon, Inc.,
Houston, TX). The silicon membrane covering one half of the HARV allows for passive
diffusion of oxygen to support cell viability and proliferation. The rotation of the HARV is
varied dependent on the size and shape of the spheroid in order to maintain a state of free-
fall or solid body rotation under a 1-g-force environment. HaCaT cells were initially rotated
at 15.0–16.5 rpm using the RCCS-4SCQ system for 8–12 h and then increased to 18.0–20.0
rpm. This process produces spheroids that are 0.75–0.95 cm in diameter. After 20–24 h,
fresh DMEM was replaced in the HARVs containing aggregated HaCaT cells. In parallel,
B16.F10 cells were grown in McCoy’s media and SKMEL-5 were grown in MEM, both
containing 0.2% gentamycin and 10% FBS, separately in two T275 flasks. Upon confluence,
1–2 × 106 cells were harvested and then injected into 2 day old HaCaT spheroids and used
for EP procedures.
2.3. TdT and immunohistochemistry (IHC) assay
The TdT-FragEL DNA Fragmentation Detection assay (Calbiochem, San Diego, CA) was
performed on paraffin embedded samples to identify cells undergoing cell death followed by
a double IHC staining to specifically differentiate apoptotic cells from viable cells. The
assay was performed per manufacturer’s instructions; a positive and negative control was
performed simultaneously with the assay. For the positive control, DNAse I (Promega,
Madison WI) was used to intentionally nick the DNA ends; the negative control was
deficient of the TdT reaction mix. Briefly, the samples on the slide were deparaffinized in
xylene and rehydrated by immersing slides in different concentrations of ethanol (Sigma–
Aldrich St. Louis, MO). The sections were permeabilized using 1:100 2 mg/ml Proteinase K
(Thermo Sci Waltham, MA) in 10 mM Tris pH 8, then blocked with 30% hydrogen peroxide
(Thermo Scientific, Waltham, MA) in methanol (Sigma–Aldrich, St. Louis, MO). The
sections were labeled with TdT labeling reaction mix, conjugated with Strep-HRP and
developed by 3,3′Diaminobenzidine (DAB) solution. For double IHC staining, 1:200
primary mouse anti-human AE1/AE3 antibody was diluted in 2.5% normal goat serum
(Molecular Probes, Carlsbad CA), while secondary goat anti-mouse IgG AP was diluted in
1:50 goat serum. All slides were developed using Fast Red (Thermo Scientific, Waltham,
MA). Sections were incubated with 1:100 primary antibody S100 goat anti-mouse (sc-7849
Santa Cruz Biotech, Santa Cruz CA) diluted in 2.5% rabbit serum (Molecular Probes,
Carlsbad CA). The sections were incubated with 1:20 secondary rabbit anti-goat IgG HRP
(HAF017 R&D Systems, Minneapolis MN) in rabbit serum and developed using DAB. All
sections were counterstained with methyl green, mounted using Permount (Fisher,
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Pittsburgh PA) and then observed under a light microscope. The methyl green counter-stain
produced a tan or blue-green stain for viable cells and DAB stained the nucleus dark brown
to signify cells had undergone pseudo-apoptosis. Viable cells were counted using an ocular
lens micrometer at 200× Magnification (Mag.) [10].
2.4. Plasmid delivery to 3D spheroid
Stable spheroids were removed from the HARV after 48 h and placed into a chamber slide.
The fluid-filled, malleable spheroid laid convex on the chamber slide and was then coated
with about 500 µl of fresh DMEM (Atlanta Biologicals, Lawrenceville, GA) which was
sufficient to maintain the spheroid in liquid during the injection and EP procedure. A 25-
gauge 5/8 inch needle attached to a 1 mL-syringe (BD Biosciences, Franklin Lakes, NJ) was
used to inject 50 µl containing 3–5 × 106 B16.F10 in McCoy’s media or SKMEL-5 in MEM
media and 1.0 mg/ml of pEGFP-N1 or phIL-15. The needle was inserted into the spheroid to
a depth of 3–5 mm from the surface towards the center. This was a single point injection
with sufficient volume and placement to ensure equal delivery of cells and plasmid within
the spheroid. The EP electrodes were situated so that the injection site was in the center of
the array. The spheroids were electroporated with different electrode arrays with varying
characteristics (Table 1). These specific arrays were chosen to simulate how electroporation
would be applied in vivo. The non-penetrating arrays are typically utilized to deliver
plasmid DNA to skin while penetrating arrays are typically utilized for tumors and muscle
among other tissues [22]. The 6-needle array has been used for delivery of plasmids to
tumors. The electrodes are typically inserted into the skin surrounding the tumor. Since this
was not possible with the spheroid, a six-plate electrode (6-PE) was used and the electrodes
were placed against the sides of the spheroid. Previous studies have demonstrated that
rotating the field around the array can enhance delivery [23,24]. Therefore for each of the
arrays, the pulses were administered in different directions. For the 6-PE and 6-needle array,
the pulses are applied between 4 of the 6 electrodes (forming a rectangle) and each pulse is
applied in a direction that is 60 degrees from the previous one [24]. Thus, after 6 pulses, a
full 360° rotation is completed. For the 4PE, 4 pulses are applied across two plates then an
additional 4 pulses applied across the 2 perpendicular plates. For the 4-needle array, three
pulses are applied in each of four directions. First, pulses are applied across the 2.5 mm gap,
then across each diagonal, and then finally across the 5 mm gap for a total of 12 pulses. The
applied voltage is based on the gap between the electrodes to achieve the desired nominal
field strength (V/cm). The electrode arrays were placed into (penetrating) or around (non-
penetrating) the tissue of interest. To administer the voltage, a BTX830 square-pulse wave
direct current generator was utilized. After EP was complete, 1–2 mL of 70% McCoy’s +
30% DMEM or 30% MEM complete media was added to the chamber slide, covered and
placed into a 1.5% CO2 37 °C humidified incubator. The spheroids were monitored and
harvested 24–48 h after transfection for analysis.
2.5. Western blots
Ready-gels (4%–15%) and transfer blot apparatus (Biorad Hercules, CA) were used to
detect protein markers E-cad (MAB3199Z, Millipore, Billerica, MA), Cyto-8 (sc-8020,
Santa Cruz Biotech, Inc., Santa Cruz, CA) and Beta Actin (#4967, Cell Signaling, Danvers,
MA). Tumor lysate proteins were separated using 110V–120V. Immobilon PVDF
Membrane and detection reagents were purchased from LI-COR Biosci (Lincoln, NE).
Proteins were transferred onto the membrane at 110V and blocked with blocking buffer. The
membrane was incubated with primary antibody at 1:2000 (E-cad) or 1:500 (Cyto-8) on a
shaker, at room temperature overnight. After 16–18 h, 1:15,000 0.5 mg goat anti-mouse IR
Dye 800CW NHS Ester was added as a secondary antibody. An Odyssey Infrared Imaging
System (LI-COR Biosci, Lincoln, NE) was used to detect fluorescently labeled bands.
Stripping reagent was used between different primary antibodies. Protein bands were
Marrero and Heller Page 4













normalized against 1:5000 Beta Actin (Cell Signaling Danvers, MA). The expression of
proteins were analyzed against positive control MCF-7 human breast cancer cell line, which
is known to express both human Cyto-8 and E-cad, while negative control B16.F10 does not
express human Cyto-8 or E-cad.
2.6. Stereoscope analysis
Following formation of HaCaT spheroids (Day 2), both pEGFP-N1 and B16.F10 cells were
injected into spheroids and immediately electroporated with the 6-PE using different
electroporation parameters (see results). An Olympus BX51 microscope and a Leica
MZFLIII Stereoscope with digital cameras were used to analyze GFP protein expression in
spheroids.
2.7. Immunofluorescence staining
Spheroids were collected at 24–48 h, snap-frozen and cryo-sectioned. Samples were labeled
with 1:1000 DAPI (Sigma–Aldrich, St. Louis, MO) to visualize all cells, blocked with 2.5%
chicken serum (Thermo Scientific, Waltham, MA), incubated with primary antibody 1:100
AE1/AE3 (MAB3412 Millipore, Billerica, MA) and then incubated with 1:100 secondary
antibody chicken anti-mouse IgG Rhodamine (sc-2861, Santa Cruz Biotech, Inc., Santa
Cruz, CA) on shaker at room temperature. Sections were analyzed for GFP expression using
an Olympus BX51 microscope at 200× Mag.
2.8. Flow cytometry
Spheroid aggregates were pressed through a 40 µm Nylon cell strainer (BD Biosciences,
Bedford, MA) and viability was determined using trypan blue exclusion (Fisher Scientific,
Pittsburg, PA). For detection of live/dead cells, 1–3 × 106 cells were incubated with 10 µl of
propidium iodide (Immuno Chemistry Technologies, Bloomington, MN) for 30 mins and
then sampled using the FACS Aria I (BD Biosciences, San Jose, CA) to quantitate GFP
expression between groups.
2.9. In vivo intratumoral delivery
Female, 6–8 week-old C57BL/6 mice (Jackson Laboratories, Bar Harbor, ME) were
inoculated subcutaneously in the left flank with 50 µl of 1 × 106 B16.F10 cells. After 6–10
days, tumors ranged from 30 to 60 mm3. Tumor size was measured using calipers and
calculated by V = ab2π/6: (a) longest diameter and (b) shortest diameter. Mice were
anesthetized by placing animals into an induction chamber infused with a mixture of 3%
isoflurane and 97% oxygen. Anesthesia was maintained during the procedures using a
rodent mask. Mice received a single injection of 1.0 mg/ml phIL-15 at a volume of 50 µl
directly into the tumor and pulses were immediately administered using a 6-needle array
placed around the tumor (inserted into the skin surrounding the tumor). Six pulses with a
pulse width of 100 µs and a nominal field strength of 1300 V/cm (1196 V applied) or with a
pulse width of 20 ms and a nominal field strength of 500 V/cm (460 V applied) were
applied. All samples were collected after 12 h, 18 h, 24 h and 48 h; snap frozen and stored at
−80 °C until processed for ELISA.
2.10. In vivo intradermal delivery
C57BL/6 mice received a single injection of 50 µl phIL-15 administered intra-dermally and
pulses were immediately administered using the 4-PE placed around the injection site. Since
a 50 µl intradermal injection raises a 6 mm bubble in the skin, the 4-PE is designed with a 6
mm gap between electrodes to fit around this bubble. A total of 8 pulses (4 pulses in each of
two perpendicular directions) were administered at two different sets of electroporation
parameters:(1) a pulse width of 150 ms at a nominal field strength of 100 V/cm (60 V
Marrero and Heller Page 5













applied) or (2) a pulse width of 20 ms at a nominal field strength of 200 V/cm (120 V
applied). All samples were collected after 12 h, 18 h, 24 h and 48 h; snap-frozen and stored
at −80 °C until processed for ELISA.
2.11. ELISA
Monoclonal human IL-15 Quantikine kit (R&D Systems Minneapolis, MN) was performed
following the manufacturer’s instructions. Briefly, the frozen spheroids, tumor or skin were
collected, weighed, and homogenized in 500 µl-600 µl Phosphate Buffered Saline (EMD
Biosciences, Darmstadt, Germany) plus Protease Inhibitor Cocktail (Roche, Branford, CT).
The homogenate was centrifuged at 1000 rpm for 5 min at 4 °C and the supernatant was
assayed the same day.
2.12. Statistical analysis
The results were analyzed using SPSS (IBM Chicago, IL) one-way ANOVA with post-hoc
least square difference test. Analysis was based on the means and standard deviation of 4 or
12 independent experiments depending on the assay.
3. Results and discussion
3.1. Stability of 3D model construct
HaCaT cells (50 × 106 cells) were injected into the bioreactor and aggregated into
approximately 1 cm diameter “tissue-like” construct after 24 h. The HARV was initially set
to rotate at 15.0–16.5 rpm, and 8–12 h later the rotation of the HARV was increased to 18.0–
20.0 rpm, which promoted a stable solid body rotation with minimal bouncing. The HARV
allows cellular growth in a microgravity environment through the use of solid body rotation.
Placing the cells in this environment facilitated aggregation of the cells into a spheroid. The
rotation of the HARV is such that the spheroid is in a constant free-fall, essentially floating
in place, keeping it away from the walls of the HARV while the media rotates around with
minimal interference and shear. The HARV’s constant rotation stabilized the 3D construct
within 48 h; this stability time point was determined by observations of HaCaT spheroid
formation for up to 15 days (d). After 48 h, HaCaT spheroids were injected with 2–3 × 106
mouse B16.F10 melanoma or human SKMEL-5 melanoma cells. At 4-6d post inoculation,
both B16.F10 and SKMEL-5 spheroids demonstrated a heterogeneous population of both
cell types (Fig. 1a) [10]. A TdT viability analysis was performed on paraffin sections of the
SKMEL-5 cells (Fig.1b). to complement the viability assay previously performed on the
B16.F10 cells analyzed in Marrero et. al To further identify SKMEL-5, cells were detected
with an HRP conjugated antibody that stained surface marker S100 brown, while HaCaT
cells stained red, detected by an AP conjugated antibody specific for the AE1/3 surface
marker. Nuclei, stained tan in viable cells; apoptotic nuclei stained dark brown. Greater than
80% of SKMEL-5 cells remained viable after 6d, comparable to the results obtained from
the TdT assay performed on B16.F10 in the previous study [10]. Additionally, using trypan
blue staining we observed that HaCaT spheroid aggregates residing alone in the HARV
reached terminal differentiation after 5–7d. Multiple experiments and observations
confirmed that HaCaT spheroids injected with melanoma remained stable in the HARV and
for up to 15d.
3.2. Demonstration of cross talk between cells in 3D tumor model
The expression of differentiation marker cytokeratin 8 (Cyto-8) and adherent protein marker
E-cadherin (E-cad) were analyzed to confirm cross talk between two different cell
populations coexisting in a 3D culture. Cyto-8 and E-cad proteins are produced by both
mouse and human keratinocytes [25,26]. Cyto-8 functions to maintain structural integrity,
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indicates epithelial differentiation and characterizes malignancy of tumors [27], while E-cad
up-regulates the adherent properties in keratinocytes and melanocytes as well as cancerous
cells like melanoma [8,12,28–30]. We analyzed expression levels of cyto-8 and E-cad by
western blot analysis 2–4d after inoculation (Fig. 1c). All band intensities were compared to
the HaCaT only group and all protein expression was compared to the MCF-7 human breast
cancer cell line, which is known to express both human Cyto-8 and E-cad. The mouse
proteins of the B16.F10 cells do not cross react with human Cyto-8 or E-cad antibodies and
served as a negative control. The Cyto-8 differentiation marker presented consistently low
band densities, <1-fold in groups HaCaT + B16.F10 and HaCaT+SKMEL-5 compared to
HaCaT alone on days 2 and 4, suggesting that the decrease of Cyto-8 resulted from the
reduced HaCaT terminal differentiation while in the presence of melanoma [31–33].
Furthermore, we observed a 2.3-fold increase of adhesion protein E-cad in HaCaT +
B16.F10 on Day 2 and 1.9-fold increase on Day 4. However, there was a slightly lower level
of E-cad <1-fold in HaCaT+SKMEL-5 on Day 2 and 4. Studies have shown that SK-MEL5
produce less than normal levels of E-cad even in the presence of keratinocytes [8,30,33].
Therefore, SK-MEL5 cells act as a negative control for E-cad expression. We also observed
that the HaCaT spheroid remained stable while in the presence of B16.F10 expansion for up
to 15 days [10]. Therefore, Fig. 1c supports that a slight decrease in Cyto-8 from group
HaCaT + melanoma compared to HaCaT is observed and suggests that actively proliferating
melanoma cells retard HaCaT terminal differentiation and increase E-cad, helping to
maintain the structural integrity of the spheroid for up to 15 days [10,32]. We also observed
that both proteins were readily up-regulated on day 2 compared to day 4 in all groups,
suggesting that protein production was regulated by keratinocytes during early stages of
melanoma growth. These data support the conclusions in our previous study, where we
found that B16.F10 cells produce dendrite-like appendages during the immunofluorescence
analysis, indicating the potential for cross talk between HaCaT and B16.F10 [10].
3.3. Analyzing plasmid delivery and differences in expression
To evaluate the applicability of the in vitro 3D model to in vivo gene transfer approaches,
we delivered a pEGFP-N1 into HaCaT spheroids using different EP conditions, then 24 h
later GFP protein expression was analyzed using a fluorescent Leica MZFLIII stereoscope
(Fig. 2). A 4-needle electrode array, a 4-PE array or a 6-PE array were utilized to test several
sets of EP conditions on the epidermal-like HaCaT cells [34]. We observed low GFP
expression levels following delivery of pEGFP-N1 into the HaCaT spheroid using the 4-
needle array and EP parameters originally designed for muscle delivery; with this array [34],
twelve 20 ms pulses administered in multiple directions at a nominal field strength of 100 V/
cm (Fig. 2a,b). Low expression was also observed following delivery with the 4-PE utilizing
EP parameters designed for skin delivery [23]. For these pulses, two sets of four pulses were
delivered in perpendicular directions. Either 150 ms pulses at a nominal field strength of 100
V/cm or 20 ms pulses at a nominal field strength of 200 V/cm were applied (Fig. 2c). Both
combinations of electrode and pulse parameters demonstrated low GFP intensity and
distribution amongst cells located near the surface of the spheroid or near the site of
electrode placement (Fig. 2b,c). We then tested delivery techniques using the 6-PE utilizing
EP parameters previously established to deliver to tumors in vivo. Six, 100 µs pulse width
with a nominal field strength of 1300 V/cm (HVSP High Voltage Short Pulses) or six 20 ms
pulse width with a nominal field strength of 500 V/cm (LVLP Low Voltage Long Pulses)
were applied [35]. Low levels of expression were observed following delivery of pEGFP-N1
into spheroids containing only HaCaT cells. To determine if the low levels of expression
was specific for HaCaT cells, the procedure was modified by mixing 1.0 mg/ml pEGFP-N1
and B16.F10 together, then simultaneously injecting the mixture into the HaCaT spheroid,
followed immediately by EP using the 6-PE. Interestingly, an increase in GFP levels was
observed compared to the HaCaT spheroid alone (Fig. 2d,e). Higher expression was
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observed in melanoma cells than the keratinocytes within the spheroid. The administration
of plasmid + B16.F10 + EP together enhanced GFP production and distribution in vitro.
Differences in transfection levels were identified when delivering pEGFP-N1+B16.F10 with
the two sets of EP parameters. In the spheroids receiving HVSP pulses (Fig. 2d), expressing
cells were concentrated in two small locations near the injection site, while in the spheroids
that received pulses with LVLP parameters, many more cells were transfected at the point of
injection and throughout the spheroid where B16.F10 cells were located (Fig. 2e–g). It is
important to note that the spheroid remained stable during the EP procedure as well as after
the procedure for up to 24–48 h. These time frames allowed sufficient time to analyze the
effectiveness of EP delivery.
3.4. Evaluating pEGFP-N1 delivery and GFP protein distribution
To confirm which cell types were transfected with pEGFP-N1, spheroids were collected 24
h after EP and cryo-sectioned for fluorescent imaging. We observed higher levels of GFP
expression and distribution in the LVLP group compared to the HVSP group utilizing the 6-
PE (Fig. 3a–f). The images show that spheroids electroporated with LVLP (Fig. 3a)
expressed higher levels of GFP throughout the spheroid, towards the center and within
loosely suspended B16.F10 cells injected into of the spheroid (Fig. 3b–c). Spheroids
electroporated with HVSP (Fig. 3d) produced higher expression than the 100 V/cm and 200
V/cm groups in Fig. 2a–c, but fewer cells were transfected (Fig. 3e–f). Expression was
observed mainly at the site of injection. We also observed that B16.F10 cells were more
readily transfected with a lower electric field 500 V/cm and longer pulses 20 ms compared
to higher electric field 1300 V/cm with shorter pulses 100 µs. In this model, utilizing a lower
electric field and longer pulse width resulted in higher expression. In addition, it is highly
probable that applying the electric field over a larger area, for example 0.8 cm–1 cm,
resulted in delivery of plasmid DNA to more cells at one time. Utilizing an applicator such
as the 6-PE allowed for even rotation of the field encompassing multiple directions. The
amplitude of the applied voltage needed to permeabilize a cell membrane is inversely
proportional to the radius of the cell. Since cells are not spherical, the direction of the field
could expose either a long or short radius of the cell, therefore, by rotating the field
increases the chance of exposing the long axis of the cell to the field and increasing the
chance of inducing permeabilization [6,7,22–25,34,35]. The results obtained in this study
confirmed that specific EP conditions and applicators are required to achieve desired
delivery and subsequent expression between varying cell types such as HaCaT and B16.F10.
3.5. GFP differential expression between HaCaT and B16.F10
To evaluate GFP distribution more closely, we used additional fluorescent labels to analyze
GFP expression using the LVLP conditions (Fig. 4a). The nuclei of cells were labeled with
DAPI, which emits a blue signal when excited by a mercury lamp, and the HaCaT cells were
labeled with rhodamine conjugated cyto-keratin AE1/3 antibody, which emitted a red signal,
for contrast. The negative control slides showed no auto-fluorescence emitted from cells in
the FITC (Fig. 4b) or TRITC (Fig. 4c) channels. The sample slides showed specific GFP
expression in the FITC channel (Fig. 4d) and specific rhodamine labeled HaCaT in the
TRITC channel (Fig. 4e). The DAPI and FITC channels merged together demonstrated the
location of GFP expression amongst all cells (Fig. 4f). While merging the FITC and TRITC
channels, demonstrated specific GFP expression between different cells types. The red
fluorescing HaCaT cells co-localized with green GFP to produce an orange fluorescence,
indicating that HaCaT cells were transfected. Cells that emitted exclusively green indicated
only melanoma cells were transfected with pEGFP-N1 (Fig. 4g,h). Merging the FITC,
TRITC and DAPI channels showed localization of all cells compared to pEGFP-N1
transfection (Fig. 4i,j). Based on these observations, many more melanoma cells than
keratinocytes expressed GFP.
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Flow analysis was utilized to quantitate GFP expression levels between four groups. All four
groups received an injection of pEGFP-N1 and were further divided as follows: 1) HaCaT
cells (no EP), 2) B16.F10 cells (no EP), 3) HaCaT + B16.F10 + EP HVSP and 4) HaCaT +
B16.F10 + EP LVLP. Samples were collected 24 h after delivery was performed to
spheroids and processed by flow analysis on the same day (Fig. 5). This experimental
procedure was performed four times. Population gates were drawn around live HaCaT +
B16.F10 cells measuring 100,000 events (Fig. 5a), the H-gate was drawn to exclude
propidium iodide stained dead cells and include the unstained live cells. A quadradic-gate
was used to distinguish between positive and negative GFP expressing populations (Fig. 5b).
A histogram plot was statistically analyzed using FlowJo software for Mean Fluorescent
Intensities (MFI). GFP MFI levels for HaCaT + B16.F10 + EP HVSP and LVLP groups
were 4.2-fold and 6.8-fold respectively higher than HaCaT control (Fig. 5c,d). The LVSP
group resulted in 1.6-fold higher GFP expression than the HVSP groups (Fig. 5 and
Supplementary Material Online Fig. 1). Evaluation of the mean MFIs from the four
independent experiments showed that HaCaT + B16.F10 transfected with HVSP expressed
GFP 3.2-fold higher and LVLP expressed a significant 7.3-fold more GFP than HaCaT (Fig.
5e).
3.7. Testing specific delivery of phIL-15 In vitro
To test effective EP conditions obtained from the GFP experiments; we next delivered
phIL-15 into the 3D tumor model and compared transfection efficiencies to the GFP
experiments. The goal was to translate the most effective EP conditions and expression
kinetics into in vivo studies. The spheroids were injected and simultaneously electroporated
with phIL-15 + B16.F10 (Fig. 6). Both the spheroid and the media were collected after 24–
48 h and tested for hIL-15 protein production by ELISA analysis. Expression levels of
hIL-15 were compared between the HaCaT alone and HaCaT + B16.F10 spheroids under
the following delivery conditions: 1) control, 2) phIL-15 injection alone, 3) phIL-15 +
HVSP and 4) phIL-15 + LVLP. Fold-changes between groups were calculated and the
results were utilized to compare experimental groups to HaCaT control or HaCaT phIL-15
injection only groups. Low levels of hIL-15 expression were detected in HaCaT spheroid
(absent of B16.F10 cells) lysate in the injection only, phIL-15 + HVSP and phIL-15 + LVLP
groups. Higher levels of IL-15 were detected in the HaCaT + B16.F10 phIL-15 + HVSP and
HaCaT + B16.F10 phIL-15 + LVLP groups. The HaCaT + B16.F10 phIL-15 + LVLP group
demonstrated significant 3.0-fold and 4.1-fold expression increase at 24 h and 48 h,
respectively (Fig. 6a). The media which contained the spheroids during EP and subsequent
incubation was also tested. For the spheroids containing only HaCaT cells, we observed a
1.3-fold increase in the phIL-15 + HVSP group and 2.6-fold from phIL-15 + LVLP group at
24 h. For the media collected from the HaCaT + B16.F10 spheroids, there was a slight
increase in hIL-15 expression in the phIL-15 + HVSP group, while the phIL-15 + LVLP
group demonstrated a significant 10.4-fold and 14.9-fold increase at 24 h and 48 h,
respectively (Fig. 6b). Overall hIL-15 expression levels were much higher in the melanoma
cells than in the keratinocytes as observed in vitro. One interesting rationalization for this
phenomenon is loosely suspended B16.F10 cells injected into a spheroid were more likely to
be transfected with plasmid using the 6-PEor 6-needle electrode conditions than tightly
organized HaCaT cells forming a less permeable barrier [7]. In addition, investigators have
reported that electric fields fired in multiple directions within a tissue increases the number
of cells that are permeabilized [6,7,22–25,34,35]. Therefore, based on our experiments,
loosely adherent B16.F10 cells exposed to the multi-directional electric field of the 6-PE
were more likely to take up the plasmid than highly adherent HaCaT cells.
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3.8. Comparing transfection Efficiencies of phIL-15 delivery in vivo
The delivery of plasmids in vitro to a monolayer of cells is not representative of the delivery
process in vivo. We predicted that the 3D model would serve as a good indicator to
characterize phIL-15 transfection efficacy and could then utilize this information to translate
effective delivery conditions in vivo. For these studies, we used C57BL/6 mice to test EP
delivery parameters on skin and tumor sites at different time points (Fig. 7). Intradermal
delivery using a 4-PE showed a 1.9-fold increase of hIL-15 at 12 h and 17.9-fold increase at
18 h in group phIL-15 + EP with eight 150 ms pulses at 100 V/cm, while phIL-15 + EP with
eight 20 ms pulses at 200 V/cm showed a 2.6-fold increase at 12 h and 38.2-fold increase at
18 h compared to intradermal phIL-15 injection without EP. Intratumoral delivery using a 6-
needle penetrating electrode (similar to 6-PE in vitro) delivering phIL-15 + EP with six 20
ms pulses at 500 V/cm showed significant 8.9-fold increase at 12 h and 9.2-fold increase at
18 h compared to tumor phIL-15 injection. Intratumor delivery of phIL-15 + EP with six
100 µs pulses at 1300 V/cm although not statistically significant, demonstrated the highest
expression at 12 h with 4.7-fold and 4.8-fold increase at 18 h compared to intratumoral
phIL-15 injection without EP. The results obtained indicated a difference in transfection
efficacy between skin and tumor as well as differences in when different EP parameter sets
were used. These findings were similar to those observed with the in vitro 3D studies (Figs.
6 and 7). Based on these observations, the EP parameters that stimulated high levels of
IL-15 expression in the skin were 200 V/cm, 20 ms pulses at 18 h and in the tumor were 500
V/cm, 20 ms pulses at 12 h. Interestingly, a decrease in expression of IL-15 was observed in
the in vivo setting but not in the in vitro model. Since in vivo, there is an active immune
system, it is possible that the delivery of phIL-15 to the tumor resulted in some cell death
which reduced the expression. An additional possibility is that since IL-15 expression is
highly controlled by many regulatory factors in vivo, the resulting IL-15 protein expression
is short-lived [36]. The results observed with the in vitro 3D model supports this as a
reduction of IL-15 expression, which was not seen in vitro in the absence of these in vivo
factors [37,38].
4. Conclusions
Skin and tumor cell types together can serve as a useful 3D tumor model that can be used to
establish gene delivery techniques for translation to in vivo applications. In the studies
reported here, we addressed the types of cellular signaling experienced from two different
cell populations when introduced into a large-scale, free-floating 3D tumor model, in hopes
of understanding how to link the biology of cells grown in culture to naturally occurring
cells in the body. The development of such a practical and stable organotypic 3D tumor
model could serve as a useful tool in the field of tissue engineering that may predict the
outcomes of applications designed for in vivo studies. The ability of keratinocyte and
melanoma cells to undergo signaling interactions such as proliferation, differentiation, and
cross talk communication while residing in the spheroid is indicative of cells’ ability to
mimic functional properties in vivo. Furthermore, the information gathered from this in vitro
3D tumor model may benefit future studies, allowing exploration of many in vivo processes
such as examining independent pathway systems to understand regulatory signaling before
translating to studies in vivo.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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The 3D spheroid forms a stable and functional tumor model. (a) 50 × 106 HaCaT cells
injected into the HARV formed a stable spheroid within 1–2 days. The spheroids injected
with 3 × 106 of B16.F10 [10] or SKMEL-5 cells formed a tumor spheroid within 6 days.
Each experiment was performed at least 3 times. (b) Viability of HaCaT injected with
SKMEL was tested using a TdT assay. Each experiment was performed at least 3 times.
Magnification (Mag) 400×. (c) Western blot analysis was used to test the functionality of
cells residing in the 3D model. HaCaT, HaCaT + B16.F10 and HaCaT+SKMEL-5 were
immunoblotted for the presence of E-cad and Cyto-8 proteins on days 2 and 4. Positive
control MCF-7 breast cancer cells and negative control B16.F10 cell lysate tested the
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specificity of primary antibody proteins markers E-cad and Cyto-8. Supernatant of spheroid
lysate was normalized by BCA Protein assay kit and 32 µg of total protein was loaded into
the wells of the gel. All samples were normalized against Beta Actin and fold change was
determined by densitometry analysis comparing band density to HaCaT only control group
on days 2 and 4, using Quant one software. WB experiments were performed at least 6
times. Scale bars, 1 cm (a); 200 µm (b).
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Delivery of pEGFP-N1 into spheroids using EP enhances GFP expression. (a) A stable
HaCaT spheroid formed after 2 days was injected with pEGFP-N1 and EP was performed
using a 4-needle electrode applying twelve 150 ms pulses at 100 V/cm to observe GFP
expression. Mag 16×. (b) This HaCaT spheroid was analyzed 24 h after transfection to
observe GFP expression. Mag 80×. (c) The HaCaT spheroid injected with pEGFP-N1 and
EP with 4-PE applying eight 20 ms pulses at 200 V/cm, was harvested after 24 h. GFP
expression was found near the external surface. Mag 48×. (d) HaCaT spheroid
simultaneously injected with 50 µl 1.0 mg/ml pEGFP-N1, 3–5 ×106 B16.F10 and
electroporated with six 100 µs pulses at 1300 V/cm applied with the 6-PE. Analyzed was
performed after 24 h. Mag 32×. (e) HaCaT spheroid simultaneously injected with 50 µl of
1.0 mg/ml pEGFP-N1, 3–5 × 106 B16.F10 and electroporated with six 20 ms pulses at 500
V/cm applied using the 6-PE. Analysis was performed after 24 h. Mag 32×. (f) Expression
was observed proximal to the site of injection. Mag 40× and (g) Distal site of injection Mag
40×. Images were representative of 5 experiments. Scale bars, 2 mm (a,d,e); 1 mm (b,c,f,g).
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GFP distribution in 3D tumor model. (a) Analysis of GFP distribution from the LVLP group
used to facilitate delivery of pEGFP-N1 into a 0.8–1.0 cm spheroid containing HaCaT +
B16.F10. Spheroid samples were collected 24 h after transfection, Mag 32×. (b–c) Cryo-
section analysis of HaCaT + B16.F10 transfected with pEGFP-N1 at LVLP, for contrast the
nuclei were labeled with DAPI. (d) EP analysis of GFP distribution from HVSP group was
used to deliver pEGFP-N1 into a spheroid containing HaCaT + B16.F10. Mag 32×. (e–f)
Cryo-section analysis of HaCaT + B16.F10 transfected with pEGFP-N1 with HVSP. An
Olympus (Center Valley, PA) microscope with camera was used to capture images at Mag.
200×. Sections were cut 8–10 µm thick. These images are representative of 2 out of 5
experiments performed n = 8–10 per group. Scale bars, 2 mm (a,d); 50 µm (b); 200 µm
(c,e.f).
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GFP expression analysis in 3D tumor model. Efficiency of pEGFP-N1 delivery was
analyzed by fluorescence imaging and showed increased GFP distribution when delivered
with the 6PE using LVLP parameters after 24 h (a–j). (a) Stereomicroscope image of a 0.8–
1.0 cm HaCaT spheroid + B16.F10. Melanoma cells were indicated by dark brown spots,
HaCaT cells were indicated by a tan color and successfully transfected cells produced green
fluorescence. Mag 96×. (b) Negative control FITC channel tested non-specific secondary
binding in the absence of primary antibody. (c) Negative control in the TRITC channel. (d)
GFP expression alone in the FITC channel. (e) Cytokeratin AE1/3 rhodamine antibody
specifically labeled HaCaT, visualized in the TRITC channel. (f) Merged image of DAPI
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blue and GFP green channels. (g–h) Merged image GFP green, DAPI blue, and Cytokeratin
red channels; overlay of images produced a yellow or orange fluorecence, HaCaT cells
lacking GFP expression appeared red and GFP expressing B16.F10 cells appeared green. (i–
j) Overlay of red HaCaT and green GFP produced a orange fluorescence signifying that
HaCaT were labeled, while yellow or green specified B16.F10 cells expressing GFP. An
Olympus BX51 microscope with camera was used to take pictures at Mag 100× (f) and
200× (b–e,g–j). Sections were cut 8–10 µm thick; images are a representation 8–10
experiments performed. Scale bars, 2 mm(a); 200 µm (b,f); 100 µm (c–e, g–j). (For
interpretation of the references to colour in this figure legend, the reader is referred to the
web version of this article.)
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Flow cytometry quantifies high levels of GFP expression from HaCaT + B16.F10 spheroids
transfected with pEGFP-N1 after 24 h. The spheroids were pressed through a 40 µm nylon
screen, collected, and evaluated for viability using trypan blue exclusion. Cells were labeled
with propidium iodide to gate live cells. FlowJo software was used to analyze flow data. (a)
Events recorded for P1 gate 113,290 cells, showing location of HaCaT + B16F10 cells
(77.2%). (b) Quadratic gate divided 87,500 live cells into positive and negative populations
and presence or absent of GFP expression. In quadrant 2, pEGFP-N1 transfected cells
showed 1.88% expression (Additional P1 and Q were analyzed in Supplementary material
online Fig. 1). (c) One-dimensional histograms measures average MFI in HaCaT and HaCaT
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+ B16.F10 + HVSP groups, demonstrating a 4.2-fold increase in GFP expression. (d)
Histogram shows overlapping HaCaT control with HaCaT + B16.F10 EP at 500 V/cm and
20 ms demonstrating a 6.8-fold increase in GFP expression. (e) Graphical representation of
all GFP MFIs analyzed from 4 independent experiments. HaCaT + B16.F10 + LVLP
showed 6.8-fold statistically significant (*p < 0.001) increase in GFP compared to HaCaT
control. HaCaT+16.F10 + HVSP showed an insignificant 2.6-fold increase compared to
HaCaT control cells. Flow analysis readings were repeated in triplicates for each sample
thus fold change varied between the readings. Error bars were measured as standard
deviation between samples in the same group. (For interpretation of the references to colour
in this figure legend, the reader is referred to the web version of this article.)
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Delivery of phIL-15 into HaCaT alone and HaCaT + B16.F10 spheroids were analyzed after
24 h and 48 h by ELISA. (a) Delivery of phIL-15 into HaCaT groups on the left side of
graph (dotted line) and delivery into HaCaT + B16.F10 groups on the right side of graph
(solid line). Average total pg of protein expression was measured from spheroid lysate. The
phIL-15 + LVLP used to deliver phIL-15 into HaCaT cells demonstrated a significant
decrease of IL-15 production at 48h (*p=<0.001). Moreover, HaCaT + B16.F10 showed
significant 3.0-fold increase in phIL-15 + LVLP at 24 h and 4.1-fold at 48 h (*p=<0.001)
compared to HaCaT control. (b) Delivery of phIL-15 into HaCaT (dotted line) and HaCaT +
B16.F10 (solid line) measuring average pg/ml of protein expression in the media. We found
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that HaCaT spheroids showed similarly low levels of hIL-15 expression in the media (b) as
in the lysate (a). HaCaT HVSP had a 1.3-fold increase at 24 h (*p = 0.050) and HaCaT
phIL-15 + LVLP had a 2.6-fold increase at 24 h (*p = 0.026) compared to the HaCaT
phIL-15 injection only group. HaCaT + B16.F10 phIL-15 + LVLP increased 10.4-fold at 24
h (*p = 0.027) and 14.9-fold increase at 48h (*p = 0.001) compared to HaCaT control.
Although HaCaT + B16.F10 phIL-15 + HVSP measurements were not considered
significant, the expression levels had slight 2.3-fold increase at 24 h and 1.7-fold increase of
hIL-15 at 48 h compared to HaCaT control group. Error bars show standard deviation
between samples in the same group. (a) 4–10 independent experiments were performed (b)
4–6 independent experiments were performed.
Marrero and Heller Page 23














In vivo delivery of phIL 15 into tumor and skin compares favorably with delivery using the
3D tumor model. Expression of IL-15 was analyzed by ELISA. Tumor and skin samples
were collected at 12 h, 18 h, 24 h and 48 h. The skin samples are displayed as the first three
groups (left side of graph, dotted line) and tumor samples are displayed as the last three
groups (right side of graph, solid line). To reduce the number of mice used, delivery was
performed to four skin sites on each mouse. Each site received a 50 µl injection of 1 mg/ml
phIL-15. Skin showed significant increase in hIL-15 expression in groups phIL-15 + HVSP,
17.9-fold (*p = 0.019) at 18 h, phIL-15 + LVLP, 38.2-fold (*p = <0.001) at 18 h, 5.2-fold
(*p = 0.025) at 24 h, and 3.6-fold (*p = 0.017) at 48 h (dotted line). Mice containing one
established tumor received a 50 µl intratumoral injection of 1 mg/ml phIL-15. Significant
results were observed with phIL-15 + LVLP, 8.9-fold (*p = 0.026) at 12 h, 9.2-fold (*p =
0.006) at 18 h, and 12.7-fold (*p = 0.022) at 24 h (solid line). Error bars measured standard
deviation between samples in the same group, n = 4 tumor and n = 12 skin samples,
comparing three independent experiments.
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